Pharma Focus Asia

Fujifilm Plans to Open Large Scale Cell Culture Production Site in USA

Introduction:

FUJIFILM Corporation plans to open a new large scale cell culture manufacturing site for biopharmaceuticals with an investment of more than US$ 2 billion. The new site will be located adjacent to the existing site in USA.

Features:

The new production facility will advance the growth of its biopharmaceutical Contract Development and Manufacturing business (CDMO). In addition, the investment made in this new site helps in fulfilling the unmet medical needs with the manufacturing of new drugs.

The new production facility will be situated adjacent to the existing site and offers commercial scale automated fill-finish and assembly,  packaging and labelling services other than drug manufacturing substances.

The facility offers 8 x 20,000L bioreactors to expand with the addition of 24 x 20,000L bioreactorsfor large-scale cell culture manufacturing.

The production facility is expected to start its operation in the spring of 2025.

Specifications:

NameFUJIFILM Corporation
TypeNew Construction
BudgetUS$2 billion
Year2025
Latest Issue
Get instant
access to our latest e-book
THERMOFISHER SEACertara - Adopting the Power of AI to Drug Development ProjectsROUQETTE - Pharma Virtual LabDUPHAT 2024Thermo Fisher Scientific - Rapid Mycoplasma TestingAsia Healthcare Week 20247th Annual Pharma Project & Portfolio Management 2024CHEMICAL INDONESIA 2024INALAB 2024The Drug Safety Symposium 2024Medlab Middle East 2024ISPE Singapore Affiliate Conference & Exhibition 2024